close

Agreements

Date: 2017-05-05

Type of information: Research agreement

Compound: (epi)genetic-based assays

Company: MDxHealth (Belgium) GROW - the School for Oncology and Developmental Biology at the Maastricht University Medical Centre (The Netherlands)

Therapeutic area: Cancer - Oncology

Type agreement: research - R&D

Action mechanism: diagnostic test

Disease:

Details:

  • • On May 5, 2017, MDxHealth announced that it has signed an agreement with the Faculty of Health, Medicine and Life Sciences / School for Oncology and Developmental Biology (GROW) at Maastricht University to expand its existing research collaboration to develop commercial next generation epigenetic cancer diagnostics. Under the terms of the multi-year R&D agreement, the collaboration will focus on developing epigenetic-based assays to provide better insight in the diagnosis, staging and treatment of cancer patients. For these next generation assays, the focus will be on sample in and result out based platforms. This technology would also be applied to MDxHealth's current and upcoming liquid biopsy tests including SelectMDx™ for Prostate Cancer.
  • GROW is the School for Oncology and Developmental Biology at the Maastricht University Medical Centre (MUMC+), The Netherlands. GROW focuses on research and teaching of (epi)genetic and cellular concepts, as well as (micro)environmental factors underlying normal and abnormal development.

Financial terms:

Latest news:

Is general: Yes